Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab, Crizotinib, and Lorlatinib in Japanese Cancer Patients
jRCT2080223299Phase 2Completed
- Start
- Aug 2016
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2 trial of avelumab, crizotinib and lorlatinib in cancer. Started Aug 2016; status: completed.
02
Drugs
avelumabcrizotiniblorlatinib
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080223299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223299.